Efficacy and Safety Study of an Oral Contraceptive in Healthy Females

PHASE3CompletedINTERVENTIONAL
Enrollment

499

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

July 31, 2007

Conditions
Contraception
Interventions
DRUG

EV/DNG (Qlaira, BAY86-5027, SH T00658ID)

GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)

Trial Locations (29)

19114

Clinical Research of Philadelphia, LLC, Philadelphia

21224

Johns Hopkins Bayview Medical Center, Baltimore

23507

Eastern Virginia Medical School, Norfolk

33186

New Age Medical Research Corp., Miami

33409

Comprehensive Clinical Trials, West Palm Beach

33461

Visions Clinical Research, Palm Springs

33607

Insignia Care for Women, P.A., Tampa

46250

Physicians Research Group, Indianapolis

68510

Women's Clinic of Lincoln, PC, Lincoln

80108

Clinical Trial Center of Colorado, Castle Rock

90033

Women and Children's Hospital, Los Angeles, Los Angeles

90509

Harbor - UCLA Medical Center, Torrance

92103

Genesis Center for Clinical Research, San Diego

92108

Medical Center for Clinical Research, San Diego

94301

Lifespan Research, Palo Alto

97239

Oregon Health and Science University, Portland

97504

OB/GYN Health Center, Medford

98105

Seattle Women's: Health, Research, Gynecology, Seattle

07960

Women's Care Source, Morristown

15213-2582

University of Pittsburgh Medical Center Health System, Pittsburgh

N2C 2N9

Total Concept Health Care Inc., Kitchener

N2L 6H6

Temple Green Clinic, Waterloo

J2B 1H8

Rhodin Recherche Clinique, Drummondville

H1T 1P6

Centre d'étude clinique de Montréal Inc., Montreal

H2X 1N8

Les Gynecologues Associes, Montreal

G1S 2L6

Clinique Recherche en Sante des Femmes Inc., Québec

G9N 2H6

Clinique de Gynecologie, Shawinigan

J1H 1Z1

Diex Recherche Inc., Sherbrooke

G1V 4X7

Clinique Médicale des Campus, Ste-Foy

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY